Literature DB >> 22424907

Aspects of cognitive functioning in schizotypy and schizophrenia: evidence for a continuum model.

Mary Cochrane1, Ian Petch, Alan D Pickering.   

Abstract

This research consisted of two studies, the fundamental aim of which was to delineate the pattern of relationships between measures of cognitive task performance and both symptom subtypes in schizophrenia and their corresponding schizotypal personality traits in healthy individuals. Study 1 compared these relationships in healthy individuals using the Schizotypal Personality Questionnaire (SPQ) and Study 2 assessed the relationships between symptomatology assessed using the Scale for the Assessment of Positive Symptoms and Scale for the Assessment of Negative Symptoms (SAPS/SANS) and cognitive task performance in a group of patients with schizophrenia. The contribution of fluid intelligence to task performance was also examined. In Study 1 high levels of negative schizotypy were associated with reduced verbal fluency, and high levels of disorganised schizotypy were associated with reduced negative priming in the healthy participants. In Study 2, closely corresponding relationships between symptom measures and these tasks were found in the patients with schizophrenia. The associations between the symptom and cognitive measures were independent of the effects of fluid IQ on performance.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22424907     DOI: 10.1016/j.psychres.2012.02.010

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  18 in total

1.  The moderating effects of perceived intentionality: exploring the relationships between ideas of reference, paranoia and social anxiety in schizotypy.

Authors:  Sean C Morrison; Alex S Cohen
Journal:  Cogn Neuropsychiatry       Date:  2014-07-02       Impact factor: 1.871

2.  Relationship between executive function, attachment style, and psychotic like experiences in typically developing youth.

Authors:  Melanie A Blair; George Nitzburg; Pamela DeRosse; Katherine H Karlsgodt
Journal:  Schizophr Res       Date:  2018-03-03       Impact factor: 4.939

3.  Association of Schizotypy With Dimensions of Cognitive Control: A Meta-Analysis.

Authors:  Maria Steffens; Inga Meyhöfer; Kaja Fassbender; Ulrich Ettinger; Joseph Kambeitz
Journal:  Schizophr Bull       Date:  2018-10-15       Impact factor: 9.306

4.  Neurophysiological substrates of configural face perception in schizotypy.

Authors:  Sangtae Ahn; Caroline Lustenberger; L Fredrik Jarskog; Flavio Fröhlich
Journal:  Schizophr Res       Date:  2019-12-02       Impact factor: 4.939

5.  Examining the Psychosis Continuum.

Authors:  Pamela DeRosse; Katherine H Karlsgodt
Journal:  Curr Behav Neurosci Rep       Date:  2015-05-01

6.  Speech prosody abnormalities and specific dimensional schizotypy features: are relationships limited to male participants?

Authors:  Jeffrey S Bedwell; Alex S Cohen; Benjamin J Trachik; Andrew E Deptula; Jonathan C Mitchell
Journal:  J Nerv Ment Dis       Date:  2014-10       Impact factor: 2.254

7.  Schizotypy and psychopathic tendencies interactively improve misattribution of affect in boys with conduct problems.

Authors:  Steven M Gillespie; Mickey T Kongerslev; Sune Bo; Ahmad M Abu-Akel
Journal:  Eur Child Adolesc Psychiatry       Date:  2020-05-31       Impact factor: 4.785

8.  Exaggerated perception of facial expressions is increased in individuals with schizotypal traits.

Authors:  Shota Uono; Wataru Sato; Motomi Toichi
Journal:  Sci Rep       Date:  2015-07-02       Impact factor: 4.379

9.  Base rates, blindness, and schizophrenia.

Authors:  Steven M Silverstein; Yushi Wang; Matthew W Roché
Journal:  Front Psychol       Date:  2013-04-03

10.  Dopaminergic basis of the psychosis-prone personality investigated with functional magnetic resonance imaging of procedural learning.

Authors:  Ulrich Ettinger; Philip J Corr; Ardeshier Mofidi; Steven C R Williams; Veena Kumari
Journal:  Front Hum Neurosci       Date:  2013-04-15       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.